{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:43:17Z","timestamp":1787766197832,"version":"build-2784847793"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.clml.2013.09.015","type":"journal-article","created":{"date-parts":[[2013,9,30]],"date-time":"2013-09-30T17:50:50Z","timestamp":1380563450000},"page":"31-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Coexistence of Myeloproliferative Neoplasm and Plasma-Cell Dyscrasia"],"prefix":"10.1016","volume":"14","author":[{"given":"Jyoti","family":"Malhotra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Kremyanskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Schorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2013.09.015_bib1","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders","volume":"355","author":"Campbell","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.09.015_bib2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.09.015_bib3","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH AND IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.09.015_bib4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2796.2004.01357.x","article-title":"Trends in the incidence of chronic Philadelphia chromosome negative (ph-) myeloproliferative disorders in the city of Goteborg, Sweden, during 1983-99","volume":"256","author":"Johansson","year":"2004","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.clml.2013.09.015_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.09.015_bib6","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.09.015_bib7","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","article-title":"Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal","volume":"22","author":"Vannucchi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.09.015_bib8","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.09.015_bib9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00277-009-0899-z","article-title":"A\u00a0retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs","volume":"89","author":"Crisa","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2013.09.015_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the mayo clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2013.09.015_bib11","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance. Natural history in 241 cases","volume":"64","author":"Kyle","year":"1978","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2013.09.015_bib12","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMcp052790","article-title":"Clinical practice. Monoclonal gammopathy of undetermined significance","volume":"355","author":"Blade","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.09.015_bib13","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.09.015_bib14","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2013.09.015_bib15","doi-asserted-by":"crossref","first-page":"859","DOI":"10.4065\/79.7.859","article-title":"Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original mayo clinic series 25 years later","volume":"79","author":"Kyle","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2013.09.015_bib16","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1200\/JCO.2002.20.6.1625","article-title":"Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"20","author":"Cesana","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.09.015_bib17","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A\u00a0long-term study of prognosis in\u00a0monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.09.015_bib18","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1182\/blood.V99.5.1745","article-title":"Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells","volume":"99","author":"Zhan","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.09.015_bib19","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1182\/blood-2002-11-3385","article-title":"Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease","volume":"101","author":"Magrangeas","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.09.015_bib20","first-page":"1655","article-title":"Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma","volume":"152","author":"Ocqueteau","year":"1998","journal-title":"American J Pathol"},{"key":"10.1016\/j.clml.2013.09.015_bib21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/1097-0142(19940201)73:3<625::AID-CNCR2820730320>3.0.CO;2-A","article-title":"Plasma cell dyscrasia with marrow fibrosis. A reversible syndrome mimicking agnogenic myeloid metaplasia","volume":"73","author":"Meerkin","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2013.09.015_bib22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0002-9343(85)90307-9","article-title":"Plasma cell dyscrasia with marrow fibrosis. Clinicopathologic syndrome","volume":"79","author":"Vandermolen","year":"1985","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2013.09.015_bib23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1159\/000225590","article-title":"Multiple myeloma associated with myelofibrosis. Report of a case and literature review","volume":"38","author":"Kasimis","year":"1981","journal-title":"Oncol"},{"key":"10.1016\/j.clml.2013.09.015_bib24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/ajcp\/89.1.63","article-title":"Marrow fibrosis and multiple myeloma","volume":"89","author":"Krzyzaniak","year":"1988","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2013.09.015_bib25","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1080\/00313020701570038","article-title":"Significance of bone marrow fibrosis in multiple myeloma","volume":"39","author":"Subramanian","year":"2007","journal-title":"Pathol"},{"key":"10.1016\/j.clml.2013.09.015_bib26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF00320228","article-title":"Monoclonal gammopathy in chronic myeloproliferative disorders","volume":"58","author":"Economopoulos","year":"1989","journal-title":"Blut"},{"key":"10.1016\/j.clml.2013.09.015_bib27","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1182\/blood.V40.5.719.719","article-title":"Incidence of monoclonal proteins in\u00a0a\u00a0Minnesota community with a cluster of multiple myeloma","volume":"40","author":"Kyle","year":"1972","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.09.015_bib28","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0025-6196(11)61090-2","article-title":"Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan","volume":"82","author":"Iwanaga","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2013.09.015_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00320010","article-title":"Frequent association of idiopathic myelofibrosis with plasma cell dyscrasias","volume":"56","author":"Duhrsen","year":"1988","journal-title":"Blut"},{"key":"10.1016\/j.clml.2013.09.015_bib30","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00277-002-0577-x","article-title":"Association of monoclonal gammopathy and\u00a0polycythemia vera or essential thrombocythemia: study of a large cohort of patients","volume":"82","author":"Randi","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2013.09.015_bib31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/ajcp\/93.1.132","article-title":"Coexistent double gammopathy, myeloproliferative disorder, and malignant lymphoma","volume":"93","author":"Ornellas","year":"1990","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2013.09.015_bib32","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/ajcp\/82.4.501","article-title":"Polycythemia associated with myeloma","volume":"82","author":"Maeda","year":"1984","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2013.09.015_bib33","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/10428190500399052","article-title":"Diffuse large b-cell lymphoma as a second, clonally unrelated lymphoproliferative disease in a patient with IgM monoclonal gammopathy of undetermined significance (MGUS) and concomitant polycythemia vera rubra","volume":"47","author":"Mian","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2013.09.015_bib34","first-page":"404057","article-title":"Coexistence of plasma cell dyscrasia with prefibrotic stage of primary myelofibrosis: a case report","volume":"2011","author":"Tsirakis","year":"2011","journal-title":"ISRN Hematol"},{"key":"10.1016\/j.clml.2013.09.015_bib35","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00000441-194908000-00005","article-title":"Multiple myeloma associated with polycythemia; report of four cases","volume":"218","author":"Lawrence","year":"1949","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.clml.2013.09.015_bib36","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1699-0463.1956.tb04663.x","article-title":"Polycythaemia vera with multiple myeloma; report of a case","volume":"38","author":"Giertsen","year":"1956","journal-title":"Acta Pathol Microbiol Scand"},{"key":"10.1016\/j.clml.2013.09.015_bib37","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0002-9343(64)90094-4","article-title":"Multiple myeloma and the myeloproliferative syndromes","volume":"36","author":"Brody","year":"1964","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2013.09.015_bib38","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1097\/00007611-197611000-00036","article-title":"Multiple myeloma on polycythemia vera following radioactive phosphorus therapy","volume":"69","author":"West","year":"1976","journal-title":"South Med J"},{"key":"10.1016\/j.clml.2013.09.015_bib39","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.0954-6820.1966.tb02380.x","article-title":"Primary polycythaemia associated with multiple myeloma","volume":"445","author":"Franzen","year":"1966","journal-title":"Acta Med Scand Suppl"},{"key":"10.1016\/j.clml.2013.09.015_bib40","first-page":"349","article-title":"Essential thrombocythaemia followed by multiple myeloma in the same patient","volume":"17","author":"Kelsey","year":"1995","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.clml.2013.09.015_bib41","first-page":"ECR09","article-title":"Rare coexistence of multiple myeloma with essential thrombocythemia: report of two cases","volume":"88","author":"Majhail","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2013.09.015_bib42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/10428199509054773","article-title":"Multiple myeloma following essential thrombocythemia","volume":"20","author":"Cobo","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2013.09.015_bib43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00007611-199501000-00011","article-title":"Multiple myeloma after treatment of essential thrombocythemia","volume":"88","author":"Arlen","year":"1995","journal-title":"South Med J"},{"key":"10.1016\/j.clml.2013.09.015_bib44","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.0954-6820.1977.tb15692.x","article-title":"Thrombocythaemia and multiple myeloma. A report on two cases","volume":"201","author":"Selroos","year":"1977","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.clml.2013.09.015_bib45","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1001\/archinte.1978.03630280056019","article-title":"Myelofibrosis associated with multiple myeloma","volume":"138","author":"Coughlin","year":"1978","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clml.2013.09.015_bib46","first-page":"10","article-title":"IgD myeloma with myelofibrosis and amyloidosis","volume":"101","author":"Udoji","year":"1977","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clml.2013.09.015_bib47","first-page":"244","article-title":"IgD (lambda) multiple myeloma associated with myelofibrosis: an isolated case of nuclear physicist","volume":"37","author":"Kanoh","year":"1996","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.clml.2013.09.015_bib48","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood.V97.8.2527","article-title":"Development of a myeloproliferative disorder in a patient with monoclonal gammopathy of undetermined significance secreting immunoglobulin of the m class and treated with thalidomide and anti-CD20 monoclonal antibody","volume":"97","author":"Kyrtsonis","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.09.015_bib49","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/ajh.20870","article-title":"Association of essential thrombocythemia and chronic lymphocytic leukemia: absence of the V617F JAK2 mutation in the lymphoid compartment","volume":"82","author":"Henry","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2013.09.015_bib50","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2940.x","article-title":"B-CLL developing in a patient with PV is not affected by V617F mutation of the Janus kinase 2","volume":"77","author":"Hussein","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2013.09.015_bib51","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000338831","article-title":"No evidence for JAK2(V617F) mutation in monoclonal B cells in 2 patients with polycythaemia vera and concurrent monoclonal B cell disorder","volume":"128","author":"Stijnis","year":"2012","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2013.09.015_bib52","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1182\/blood-2011-11-390351","article-title":"Methylation of AR locus does not always reflect X chromosome inactivation state","volume":"119","author":"Swierczek","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.09.015_bib53","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clml.2011.04.001","article-title":"Essential thrombocythemia and multiple myeloma: two rare diseases in one patient","volume":"11","author":"Eskazan","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2013.09.015_bib54","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000187645","article-title":"JAK2V617F-positive essential thrombocythemia and multiple myeloma with IgH\/CCND1 gene translocation coexist, but originate from separate clones","volume":"120","author":"Kuroda","year":"2008","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2013.09.015_bib55","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.clml.2012.09.010","article-title":"A\u00a0case report of chronic myelogenous leukemia in a patient with multiple myeloma and a review of the literature","volume":"13","author":"Ragupathi","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2013.09.015_bib56","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1172\/JCI64397","article-title":"Spleens of myelofibrosis patients contain malignant hematopoietic stem cells","volume":"122","author":"Wang","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clml.2013.09.015_bib57","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/bmt.2010.157","article-title":"Multiple myeloma with concomitant jak2-positive essential thrombocythemia post-successful autologous peripheral blood hematopoietic stem cell transplant","volume":"46","author":"Holtan","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2013.09.015_bib58","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1080\/1042819021000040008","article-title":"Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies","volume":"43","author":"Barosi","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2013.09.015_bib59","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2004.08.160","article-title":"Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial","volume":"22","author":"Marchetti","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.09.015_bib60","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1200\/JCO.2009.22.6548","article-title":"Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis","volume":"27","author":"Quintas-Cardama","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.09.015_bib61","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1038\/sj.leu.2404711","article-title":"Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions","volume":"21","author":"Tefferi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.09.015_bib62","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2008.21.7356","article-title":"Pomalidomide is active in the treatment of anemia associated with myelofibrosis","volume":"27","author":"Tefferi","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.09.015_bib63","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quintas-Cardama","year":"2010","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013004369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013004369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:24:42Z","timestamp":1761870282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265013004369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S2152265013004369"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2013.09.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coexistence of Myeloproliferative Neoplasm and Plasma-Cell Dyscrasia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2013.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}